Researchers are currently experimenting with a non-coding RNA molecule called miR-34a as a new treatment for diffuse malignant peritoneal mesothelioma. DMPM is a form of malignant mesothelioma, and its growth appears to be inhibited by the miR-34a molecule.

Researchers indicate that miR-34a inhibits the ability of DMPM to migrate and grow. It also triggers the death of tumor cells. Italian researchers have published a special study that encourages further research into miR-34a in order to explore the possibility of developing a treatment.

DMPM is a prevalent type of malignant mesothelioma, accounting for 30 percent of cases. It’s also very aggressive, and most patients do not have many options when it comes to treating the disorder. Thus far, DMPM has been resistant to chemotherapy and quickly spreading. Doctors are unsure why that is.

Researchers have experimented with miR-34a by using a similar substance on animals. In those cases, they found that DMPM cell migration and growth was inhibited, and this also resulted in cell death. In addition to miR-34a, researchers are also looking into how this molecule affects the inhibition of the protein compounds AXL and c-MET.

Whenever a research sheds light on the possibility of new mesothelioma treatment options, it certainly brings hope to anyone suffering from the condition. Still, although treating the DMPM classification of mesothelioma is difficult, treatment options are available.

Illinois construction workers who need money to pay for their mesothelioma treatments, may be able to get the financial assistance they need by filing a workers’ compensation claim. A successfully navigated workers’ compensation claim could also enable sick workers to get wage replacement benefits to help them stay financially afloat while they are too sick and infirm to hold down a job.

Source: Mesothelioma Research News, “Non-coding RNA Could Lead to Treatment for Aggressive Mesothelioma, Study Says,” Alice Melao, Feb. 01, 2017